Table 3. Rebound of different treatment regimen in stage two.
| Symptoms | MF+PLA | MF+OXY | PLA+OXY | PLA+PLA |
|---|---|---|---|---|
| Nc FA | 2.6 ± 0.4 | 2.0 ± 0.2* | 2.1 ± 0.2* | 2.7 ± 0.3 |
| LA | 1.9 ± 0.3* | 0.7 ± 0.2* | 1.9 ± 0.2* | 2.5 ± 0.2 |
| LS | 2.6 ± 0.3# | 1.3 ± 0.2* | 2.6 ± 0.2# | 2.6 ± 0.3 |
| Sno FA | 2.5 ± 0.3 | 1.9 ± 0.1* | 1.9 ± 0.3* | 2.6 ± 0.4 |
| LA | 1.7 ± 0.3* | 0.8 ± 0.3* | 1.8 ± 0.2* | 2.7 ± 0.3 |
| LS | 2.7 ± 0.3# | 1.2 ± 0.2* | 2.6 ± 0.3# | 2.5 ± 0.4 |
| Rn FA | 2.3 ± 0.3 | 2.4 ± 0.2 | 2.7 ± 0.2 | 2.7 ± 0.3 |
| LA | 1.3 ± 0.3* | 0.8 ± 0.1* | 2.5 ± 0.2 | 2.5 ± 0.3 |
| LS | 2.5 ± 0.2# | 2.3 ± 0.2* # | 2.6 ± 0.3 | 2.7 ± 0.2 |
| Snz FA | 2.4 ± 0.4 | 2.3 ± 0.2 | 2.5 ± 0.3 | 2.5 ± 0.3 |
| LA | 1.1 ± 0.3* | 0.9 ± 0.2* | 2.7 ± 0.2 | 2.5 ± 0.3 |
| LS | 2.5 ± 0.2# | 2.2 ± 0.4* # | 2.6 ± 0.4 | 2.6 ± 0.3 |
| In FA | 2.1 ± 0.3 | 2.2 ± 0.3 | 2.4 ± 0.2 | 2.3 ± 0.3 |
| LA | 1.2 ± 0.2* | 0.8 ± 0.1* | 2.3 ± 0.3 | 2.4 ± 0.2 |
| LS | 2.5 ± 0.4# | 2.4 ± 0.2* # | 2.3 ± 0.1 | 2.3 ± 0.3 |
| Co FA | 1.9 ± 0.4 | 2.0 ± 0.3 | 2.2 ± 0.3 | 2.1 ± 0.2 |
| LA | 1.3 ± 0.2* | 0.9 ± 0.1* | 2.1 ± 0.2 | 2.2 ± 0.3 |
| LS | 2.3 ± 0.3# | 2.1 ± 0.3* # | 2.1 ± 0.3 | 2.1 ± 0.3 |
| TS FA | 14.2 ± 1.5 | 12.2 ± 1.8* | 13.6 ± 1.4* | 15.5 ± 1.2 |
| LA | 8.8 ± 1.6* | 4.8 ± 0.8* | 13.8 ± 1.5* | 14.9 ± 1.4 |
| LS | 15.3 ± 2.3# | 12.9 ± 1.1* # | 15.8 ± 1.6# | 15.4 ± 1.3 |
Nc, nasal congestion; Sno, snoring; Rn, runny nose; Snz, sneezing; In, itchy nose; Co, cough; TS, total score; FA, first week active treatment; LA, last week treatment; LS, last study week.
*Compared with baseline score, P < 0.05.
#Compared with last week treatment, P < 0.05.